

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: [Riggins, Cindy](#); [narin.ahmed@novartis.com](#)
Subject: BL 125646 Clinical Information Request
Date: Thursday, June 29, 2017 8:53:20 AM
Attachments: [image001.png](#)

Good morning,

Please see the information request below and provide a response by 4 pm on June 30, 2017.

1. Please provide a copy of the training materials used at site visits for sites that administered tisagenlecleucel under the IND 16130. This should include patient specific information as well as site specific requirements needed to qualify as a study site.
2. Please provide a copy of the training materials, on site and supplemental documents, that you are using for the training on new sites in anticipation of the marketing of tisagenlecleucel.
3. Please provide any recommendations that need to be in place for a site to comply with your training and preparation guidelines.

Please confirm receipt of this request.

Thank you,

Erica Giordano

Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8298
Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."